Pharma dominates global M&A activity

Mergers and acquisitions in the pharma, medical and biotech sectors have hit the highest levels in nearly 15 years, a new industry report has found. 

Figures compiled by industry analysts the Mergermarket group show global mergers and acquisitions in the pharma, medical and biotech sectors hit the highest half-year value on record since the first half of 2001. 

The US led the M&A charge, as companies scrambled to buy smaller firms and absorb their pipelines, and link up with rivals to secure greater shares of the market. 

US activity across the three sectors hit S$211.2 billion worth of deals, representing a 2.7% increase from the same period last year. 

And a separate report by Allen and Overbury found the life sciences is one of a clutch of industries where big-ticket, multi-billion dollar transactions that are highly strategic are becoming more prevalent - and are expected to multiply in the coming years. 

Life sciences deals in the first half of 2015 were worth $193 billion, it finds, making it the fourth-highest value M&A sector globally. The report concludes that there remains plenty of life in the sector, with industry consolidation often driving activity. (Más)


 Ver